Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

This study suggests that guava leaf extract may inhibit hair loss by downregulating genes involved in androgen synthesis, potentially offering a natural alternative for treating androgenetic alopecia.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This article reviews the use of 5α-reductase inhibitors for treating benign prostatic hyperplasia, suggesting potential benefits beyond symptom relief, but it reports no new clinical results.

This article discusses the role of 5-alpha-reductase inhibitors in prostate cancer prevention and highlights a medical quandary, but it reports no new clinical findings.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

The abstract reports no new results but discusses Berry's belief that most changes in breast cancer incidence are due to screening, measurement adjustments, or hormone use.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This abstract discusses treatment options for benign prostatic hyperplasia and provides no new clinical results.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

This review examines the long-term health risks of anabolic-androgenic steroid abuse in athletes, reporting various physical and psychological side effects without sufficient benefits.

In this study using Mendelian randomization analysis, researchers found no causal relationship between androgenic alopecia and prostate cancer risk, suggesting that previously observed associations in epidemiological studies might not be causal.

In this study, beagle dogs treated with hydrocortisone 17-butyrate 21-propionate ointment showed various toxic effects, including acne-like skin changes and organ atrophy, which returned to normal after a recovery period.

Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This review discusses common hair loss conditions and explores how advancements in hair follicle biology might lead to more effective treatments but reports no new results.

This review covers cell transplantation methods for genitourinary reconstruction, discussing tissue sources and complications but presenting no new clinical findings.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

This study found that a 3 mm margin around the prostate CTV may be adequate if accompanied by frequent imaging, but superior-inferior displacements were notably greater than in other directions.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

This meta-analysis found that spironolactone use was linked to a decreased risk of prostate cancer but not to a significant risk increase for several other cancers, although the evidence certainty was low.

This review discusses the roles of androgens and androgen receptor in skin diseases like acne and hirsutism, and highlights the promise of antiandrogen drugs, reporting no new clinical findings.

This review discusses current treatment methods for managing androgenetic alopecia in men and women, but reports no new clinical results, highlighting the lack of a standard treatment guide.

Finasteride slightly improves prostate symptoms but has minimal difference from placebo.